Mineralocorticoid receptor antagonism confers cardioprotection in heart failure

Current Heart Failure Reports

Volumn 10, Issue 1, 2013, Pages 36-45

  Seawell, Michael R ^a   Al Darazi, Fahed ^a   Farah, Victor ^a   Ramanathan, Kodangudi B ^a   Newman, Kevin P ^a   Bhattacharya, Syamal K ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antioxidant defenses; Calcium; Cardioprotection; Congestive heart failure; Magnesium; Mineralocorticoid receptor antagonists; Mitochondria; Oxidative stress; Potassium; Zinc

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE RECEPTOR; CATECHOLAMINE; ENALAPRIL; LOOP DIURETIC AGENT; MAGNESIUM ION; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; PARATHYROID HORMONE; PLACEBO; POLYCATION; RENIN; SALBUTAMOL; ZINC ION;

ARTICLE; CATECHOLAMINE BLOOD LEVEL; CONGESTIVE HEART FAILURE; DIURETIC THERAPY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HORMONE ACTION; HUMAN; HYPERALDOSTERONISM; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; ION TRANSPORT; OXIDATIVE STRESS; PARATHYROID HORMONE RELEASE; PLASMA RENIN ACTIVITY; POTASSIUM BALANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY HYPERPARATHYROIDISM;

EID: 84873730718     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0120-x     Document Type: Article

References (115)

1. Kamalov G, Bhattacharya SK, Weber KT. Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol. 2010;56:320-8.
2. Pitt B, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
3. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
4. Weber KT. Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms. Curr Heart Fail Rep. 2004;1:51-6.
5. •• Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. The efficacy of a mineralocorticoid receptor antagonist was evaluated in the EMPHASIS-HF trial, which consisted of patients having mild heart failure symptoms. A reduced risk of death from cardiovascular causes or hospitalization for heart failure was found.
6. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-9.
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
8. Volpe M, Tritto C, DeLuca N, et al. Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure. Circulation. 1993;88:1620-7.
9. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691-5.
10. Peacock 4th WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-26.
11. Taniguchi R, Sato Y, Nishio Y, Kimura T, Kita T. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Hear Vessel. 2006;21:344-9.
12. Sukova J, Ostadal P, Widimsky P. Profile of patients with acute heart failure and elevated troponin I levels. Exp Clin Cardiol. 2007;12:153-6.
13. Ilva T, Lassus J, Siirilä-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail. 2008;10:772-9.
14. Sato Y, Nishi K, Taniguchi R, et al. In patients with heart failure and non-ischemic heart disease, cardiac troponin T is a reliable predictor of long-term echocardiographic changes and adverse cardiac events. J Cardiol. 2009;54:221-30.
15. • Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2009;54:1715-21. Patients with decompensated heart failure having neurohormonal activation can have nonischemic cardiomyocyte necrosis with elevated serum troponins, which contributes to an ongoing adverse remodeling of myocardium, including ensuing reparative fibrosis.
16. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89:151-63.
17. Cotran RS, Kumar V, Robbins SL. Robbins pathologic basis of disease. Philadelphia: W B Saunders; 1989.
18. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138-47.
19. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301-5.
20. •• Kjeldsen K. Hypokalemia and sudden cardiac death. Exp Clin Cardiol. 2010;15:e96-9. The underappreciated importance of hypokalemia in clinical practice and its relationship to cardiac arrhythmias, both supraventricular and ventricular.
21. Struthers AD, Whitesmith R, Reid JL. Prior thiazide diuretic treatment increases adrenaline-induced hypokalaemia. Lancet. 1983;1(8338):1358-61.
22. Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207-11.
23. Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokalemia: the role of beta adrenoceptors. Am J Cardiol. 1986;57:23F-7F.
24. Ahrens RC, Smith GD. Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Pharmacotherapy. 1984;4:105-21.
25. Ryzen E. Magnesium homeostasis in critically ill patients. Magnesium. 1989;8:201-12.
26. •• Weglicki WB. Hypomagnesemia and inflammation: clinical and basic aspects. Annu Rev Nutr. 2012;32:55-71. The underappreciated importance of chronic hypomagnesemia in contributing to pathologic remodeling of myocardium and ventricular dysfunction.
27. Sheehan JP, Seelig MS. Interactions of magnesium and potassium in the pathogenesis of cardiovascular disease. Magnesium. 1984;3:301-14.
28. Solomon R. The relationship between disorders of K + and Mg + homeostasis. Semin Nephrol. 1987;7:253-62.
29. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. 1994;128:564-74.
30. 2+ signaling. Pflugers Arch. 2009;457:941-54.
31. Romani A, Marfella C, Scarpa A. Regulation of magnesium uptake and release in the heart and in isolated ventricular myocytes. Circ Res. 1993;72:1139-48.
32. Carlstedt F, Lind L, Rastad J, et al. Parathyroid hormone and ionized calcium levels are related to the severity of illness and survival in critically ill patients. Eur J Clin Invest. 1998;28:898-903.
33. Carlstedt F, Lind L, Wide L, et al. Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department. Eur J Clin Invest. 1997;27:977-81.
34. Gunnewiek JM, Van Der Hoeven JG. Cardiac troponin elevations among critically ill patients. Curr Opin Crit Care. 2004;10:342-6.
35. Chhokar VS, Sun Y, Bhattacharya SK, et al. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol. 2004;287:H2023-6.
36. Chhokar VS, Sun Y, Bhattacharya SK, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871-8.
37. Rossi E, Perazzoli F, Negro A, et al. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens. 1998;11:8-13.
38. Goodwin KD, Ahokas RA, Bhattacharya SK, et al. Preventing oxidative stress in rats with aldosteronism by calcitriol and dietary calcium and magnesium supplements. Am J Med Sci. 2006;332:73-8.
39. Vidal A, Sun Y, Bhattacharya SK, et al. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290:H286-94.
40. Selektor Y, Ahokas RA, Bhattacharya SK, et al. Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. Am J Med Sci. 2008;335:105-10.
41. Resnick LM, Nicholson JP, Laragh JH. Calcium metabolism and the renin-aldosterone system in essential hypertension. J Cardiovasc Pharmacol. 1985;7 Suppl 6:S187-93.
42. Resnick LM, Nicholson JP, Laragh JH. Calcium, the renin-aldosterone system, and the hypotensive response to nifedipine. Hypertension. 1987;10:254-8.
43. Resnick LM. Calciotropic hormones in salt-sensitive essential hypertension: 1,25-dihydroxyvitamin D and parathyroid hypertensive factor. J Hypertens Suppl. 1994;12:S3-9.
44. LaGuardia SP, Dockery BK, Bhattacharya SK, et al. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci. 2006;332:112-8.
45. Hellman DE, Kartchner M, Komar N, Mayes D, Pitt M. Hyperaldosteronism, hyperparathyroidism, medullary sponge kidneys, and hypertension. JAMA. 1980;244:1351-3.
46. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:385-90.
47. Rossi E, Sani C, Perazzoli F, et al. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884-93.
48. Rosenberg J, Pines M, Hurwitz S. Response of adrenal cells to parathyroid hormone stimulation. J Endocrinol. 1987;112:431-7.
49. Rosenberg J, Pines M, Hurwitz S. Stimulation of chick adrenal steroidogenesis by avian parathyroid hormone. J Endocrinol. 1988;116:91-5.
50. Rosenberg J, Pines M, Hurwitz S. Inhibition of aldosterone secretion by atrial natriuretic peptide in chicken adrenocortical cells. Biochim Biophys Acta. 1989;1014:189-94.
51. Brunaud L, Germain A, Zarnegar R, et al. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surgery. 2009;146:1035-41.
52. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond). 2007;113:267-78.
53. Gandhi MS, Deshmukh PA, Kamalov G, et al. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2008;52:245-52.
54. Kamalov G, Deshmukh PA, Baburyan NY, et al. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol. 2009;53:414-23.
55. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease-a review. Eur Heart J. 2004;25:1776-87.
56. Yu N, Donnan PT, Flynn RW, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf). 2010;73:30-4.
57. Sambrook PN, Chen JS, March LM, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004;89:5477-81.
58. Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology. 2009;55:601-6.
59. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab. 1997;82:106-12.
60. Stefenelli T, Mayr H, Bergler-Klein J, et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med. 1993;95:197-202.
61. Kiernan TJ, O'Flynn AM, McDermott JH, Kearney P. Primary hyperparathyroidism and the cardiovascular system. Int J Cardiol. 2006;113:E89-92.
62. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95:2172-9.
63. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
64. Alsafwah S, LaGuardia SP, Nelson MD, et al. Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci. 2008;335:292-7.
65. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35-41.
66. Schmid C, Kiowski W. Hyperparathyroidism in congestive heart failure. Am J Med. 1998;104:508-9.
67. Ogino K, Ogura K, Kinugasa Y, et al. Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure. J Clin Endocrinol Metab. 2002;87:4722-7.
68. Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41:105-12.
69. Sugimoto T, Tanigawa T, Onishi K, et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart. 2009;95:395-8.
70. Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13:626-32.
71. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J. 2010;31:1591-8.
72. •• Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009;119:2765-71. Elevations in parathyroid hormone and the presence of secondary hyperparathyroidism as contributing to increased risk of cardiovascular mortality in a large elderly male cohort followed in Sweden.
73. • Hagström E, Ingelsson E, Sundström J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12:1186-92. Elevations in parathyroid hormone as predictive of risk for congestive heart failure in the large male cohort from Sweden, emphasizing the value of monitoring serum parathyroid hormone.
74. Bell NH, Greene A, Epstein S, et al. Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest. 1985;76:470-3.
75. Sawaya BP, Monier-Faugere MC, Ratanapanichkich P, et al. Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clin Nephrol. 2002;57:51-5.
76. Zittermann A, Fischer J, Schleithoff SS, et al. Patients with congestive heart failure and healthy controls differ in vitamin D-associated lifestyle factors. Int J Vitam Nutr Res. 2007;77:280-8.
77. Zittermann A, Schleithoff SS, Gotting C, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008;10:321-7.
78. Borkowski BJ, Cheema Y, Shahbaz AU, Bhattacharya SK, Weber KT. Cation dyshomeostasis and cardiomyocyte necrosis. The Fleckenstein hypothesis revisited. Eur Heart J. 2011;32:1846-53.
79. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation. 2008;118:1946-52.
80. Carbone LD, Cross JD, Raza SH, et al. Fracture risk in men with congestive heart failure. Risk reduction with spironolactone. J Am Coll Cardiol. 2008;52:135-8.
81. Teucher B, Dainty JR, Spinks CA, et al. Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women. J Bone Miner Res. 2008;23:1477-85.
82. Kerschan-Schindl K, Strametz-Juranek J, Heinze G, et al. Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transplant. 2003;22:843-50.
83. Nishio K, Mukae S, Aoki S, et al. Congestive heart failure is associated with the rate of bone loss. J Intern Med. 2003;253:439-46.
84. Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density in patients with heart failure. Osteoporos Int. 2006;17:1420-7.
85. Frost RJ, Sonne C, Wehr U, Stempfle HU. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol. 2007;156:309-14.
86. Abou-Raya S, Abou-Raya A. Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. Arch Gerontol Geriatr. 2009;49:250-4.
87. Fisher AA, Southcott EK, Srikusalanukul W, et al. Relationships between myocardial injury, all-cause mortality, vitamin D, PTH, and biochemical bone turnover markers in older patients with hip fractures. Ann Clin Lab Sci. 2007;37:222-32.
88. Anast CS, Winnacker JL, Forte LR, Burns TW. Impaired release of parathyroid hormone in magnesium deficiency. J Clin Endocrinol Metab. 1976;42:707-17.
89. Rude RK, Oldham SB, Singer FR. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol (Oxf). 1976;5:209-24.
90. Singal PK, Kirshenbaum LA. A relative deficit in antioxidant reserve may contribute in cardiac failure. Can J Cardiol. 1990;6:47-9.
91. Kirshenbaum LA, Singal PK. Antioxidant changes in heart hypertrophy: significance during hypoxia-reoxygenation injury. Can J Physiol Pharmacol. 1992;70:1330-5.
92. Sharir H, Zinger A, Nevo A, Sekler I, Hershfinkel M. Zinc released from injured cells is acting via the Zn2 + -sensing receptor, ZnR, to trigger signaling leading to epithelial repair. J Biol Chem. 2010;285:26097-106.
93. Iwata M, Takebayashi T, Ohta H, et al. Zinc accumulation and metallothionein gene expression in the proliferating epidermis during wound healing in mouse skin. Histochem Cell Biol. 1999;112:283-90.
94. Thomas M, Vidal A, Bhattacharya SK, et al. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. Am J Physiol Heart Circ Physiol. 2007;293:H2361-6.
95. 65zinc translocation in a rat model of chronic aldosteronism. J Cardiovasc Pharmacol. 2008;51:359-64.
96. Tubek S. Role of zinc in regulation of arterial blood pressure and in the etiopathogenesis of arterial hypertension. Biol Trace Elem Res. 2007;117:39-51.
97. Golik A, Modai D, Averbukh Z, et al. Zinc metabolism in patients treated with captopril versus enalapril. Metabolism. 1990;39:665-7.
98. Golik A, Zaidenstein R, Dishi V, et al. Effects of captopril and enalapril on zinc metabolism in hypertensive patients. J Am Coll Nutr. 1998;17:75-8.
99. Arroyo M, LaGuardia SP, Bhattacharya SK, et al. Micronutrients in African-Americans with decompensated and compensated heart failure. Transl Res. 2006;148:301-8.
100. Oster O. Trace element concentrations (Cu, Zn, Fe) in sera from patients with dilated cardiomyopathy. Clin Chim Acta. 1993;214:209-18.
101. Topuzoglu G, Erbay AR, Karul AB, Yensel N. Concentrations of copper, zinc, and magnesium in sera from patients with idiopathic dilated cardiomyopathy. Biol Trace Elem Res. 2003;95:11-7.
102. Salehifar E, Shokrzadeh M, Ghaemian A, Aliakbari S, Saeedi Saravi SS. The study of Cu and Zn serum levels in idiopathic dilated cardiomyopathy (IDCMP) patients and its comparison with healthy volunteers. Biol Trace Elem Res. 2008;125:97-108.
103. Kosar F, Sahin I, Taskapan C, et al. Trace element status (Se, Zn, Cu) in heart failure. Anadolu Kardiyol Derg. 2006;6:216-20.
104. 2+ supplementation.
105. Tuncay E, Bilginoglu A, Sozmen NN, et al. Intracellular free zinc during cardiac excitation-contraction cycle: calcium and redox dependencies. Cardiovasc Res. 2011;89:634-42.
106. Turan B. Zinc-induced changes in ionic currents of cardiomyocytes. Biol Trace Elem Res. 2003;94:49-60.
107. Kamalov G, Ahokas RA, Zhao W, et al. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism. Am J Physiol Heart Circ Physiol. 2010;298:H385-94.
108. Kamalov G, Ahokas RA, Zhao W, et al. Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism. J Cardiovasc Pharmacol. 2010;55:248-54.
109. Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther. 2005;108:225-56.
110. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113:544-54.
111. Chung MJ, Hogstrand C, Lee SJ. Cytotoxicity of nitric oxide is alleviated by zinc-mediated expression of antioxidant genes. Exp Biol Med (Maywood). 2006;231:1555-63.
112. Chung MJ, Walker PA, Brown RW, Hogstrand C. ZINC-mediated gene expression offers protection against H2O2-induced cytotoxicity. Toxicol Appl Pharmacol. 2005;205:225-36.
113. Singal PK, Dhillon KS, Beamish RE, Dhalla NS. Protective effect of zinc against catecholamine-induced myocardial changes electrocardiographic and ultrastructural studies. Lab Invest. 1981;44:426-33.
114. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol. 1982;60:1390-7.
115. Chvapil M, Owen JA. Effect of zinc on acute and chronic isoproterenol induced heart injury. J Mol Cell Cardiol. 1977;9:151-9.